Lung cancer patients gain early access to promising new drug
NCT ID NCT04830202
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This program provides early access to telisotuzumab vedotin, an investigational drug, for eligible people with non-small cell lung cancer who have no other treatment options. A doctor must decide if the potential benefit outweighs the risks. The drug is given by intravenous infusion.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
telisotuzumab vedotin (ABBV-399)
What this could lead to
If this drug works, it could offer a new treatment option for people with non-small cell lung cancer who have no other suitable therapies.
What could go wrong
This is an expanded access program, not a formal trial, so data on effectiveness and safety are limited. The drug is investigational and may not work or could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER (NSCLC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.